Clinical Trial Update: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity [Phase 3]

View source ↗

Summary

A Phase 3 study of Orforglipron (LY3502970) in adults with obesity or overweight and at least one weight-related comorbidity is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 3 | Status: ACTIVE_NOT_RECRUITING